Clinical Trial Update: Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated [Phase 3]

View source ↗

Summary

Phase 3 study of magrolimab in combination with azacitidine in TP53-mutant acute myeloid leukemia was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Magrolimab (magrolimab)
• Venetoclax (venetoclax)

Snippet

Sponsor: Gilead Sciences | Conditions: Acute Myeloid Leukemia | Phase 3 | Status: TERMINATED | Results posted: 2025-02-05